284 related articles for article (PubMed ID: 15831700)
1. Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin.
Drakesmith H; Schimanski LM; Ormerod E; Merryweather-Clarke AT; Viprakasit V; Edwards JP; Sweetland E; Bastin JM; Cowley D; Chinthammitr Y; Robson KJ; Townsend AR
Blood; 2005 Aug; 106(3):1092-7. PubMed ID: 15831700
[TBL] [Abstract][Full Text] [Related]
2. In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations.
Schimanski LM; Drakesmith H; Merryweather-Clarke AT; Viprakasit V; Edwards JP; Sweetland E; Bastin JM; Cowley D; Chinthammitr Y; Robson KJ; Townsend AR
Blood; 2005 May; 105(10):4096-102. PubMed ID: 15692071
[TBL] [Abstract][Full Text] [Related]
3. The molecular basis of ferroportin-linked hemochromatosis.
De Domenico I; Ward DM; Nemeth E; Vaughn MB; Musci G; Ganz T; Kaplan J
Proc Natl Acad Sci U S A; 2005 Jun; 102(25):8955-60. PubMed ID: 15956209
[TBL] [Abstract][Full Text] [Related]
4. The molecular basis of hepcidin-resistant hereditary hemochromatosis.
Fernandes A; Preza GC; Phung Y; De Domenico I; Kaplan J; Ganz T; Nemeth E
Blood; 2009 Jul; 114(2):437-43. PubMed ID: 19383972
[TBL] [Abstract][Full Text] [Related]
5. Impact of D181V and A69T on the function of ferroportin as an iron export pump and hepcidin receptor.
Praschberger R; Schranz M; Griffiths WJ; Baumgartner N; Hermann M; Lomas DJ; Pietrangelo A; Cox TM; Vogel W; Zoller H
Biochim Biophys Acta; 2014 Sep; 1842(9):1406-12. PubMed ID: 24859227
[TBL] [Abstract][Full Text] [Related]
6. Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin.
Aschemeyer S; Qiao B; Stefanova D; Valore EV; Sek AC; Ruwe TA; Vieth KR; Jung G; Casu C; Rivella S; Jormakka M; Mackenzie B; Ganz T; Nemeth E
Blood; 2018 Feb; 131(8):899-910. PubMed ID: 29237594
[TBL] [Abstract][Full Text] [Related]
7. Non-HFE hepatic iron overload.
Pietrangelo A; Caleffi A; Corradini E
Semin Liver Dis; 2011 Aug; 31(3):302-18. PubMed ID: 21901660
[TBL] [Abstract][Full Text] [Related]
8. Molecular pathogenesis of hereditary hemochromatosis.
Liu J; Pu C; Lang L; Qiao L; Abdullahi MA; Jiang C
Histol Histopathol; 2016 Aug; 31(8):833-40. PubMed ID: 27031690
[TBL] [Abstract][Full Text] [Related]
9. Human mutation D157G in ferroportin leads to hepcidin-independent binding of Jak2 and ferroportin down-regulation.
De Domenico I; Lo E; Ward DM; Kaplan J
Blood; 2010 Apr; 115(14):2956-9. PubMed ID: 20124516
[TBL] [Abstract][Full Text] [Related]
10. Characterization of three novel pathogenic SLC40A1 mutations and genotype/phenotype correlations in 7 Italian families with type 4 hereditary hemochromatosis.
Majore S; Bonaccorsi di Patti MC; Valiante M; Polticelli F; Cortese A; Di Bartolomeo S; De Bernardo C; De Muro M; Faienza F; Radio FC; Grammatico P; Musci G
Biochim Biophys Acta Mol Basis Dis; 2018 Feb; 1864(2):464-470. PubMed ID: 29154924
[TBL] [Abstract][Full Text] [Related]
11. Reduced iron export associated with hepcidin resistance can explain the iron overload spectrum in ferroportin disease.
Viveiros A; Panzer M; Baumgartner N; Schaefer B; Finkenstedt A; Henninger B; Theurl I; Nachbaur K; Weiss G; Haubner R; Decristoforo C; Tilg H; Zoller H
Liver Int; 2020 Aug; 40(8):1941-1951. PubMed ID: 32450003
[TBL] [Abstract][Full Text] [Related]
12. Deciphering the molecular basis of ferroportin resistance to hepcidin: Structure/function analysis of rare SLC40A1 missense mutations found in suspected hemochromatosis type 4 patients.
Le Tertre M; Ka C; Guellec J; Gourlaouen I; Férec C; Callebaut I; Le Gac G
Transfus Clin Biol; 2017 Nov; 24(4):462-467. PubMed ID: 28826751
[TBL] [Abstract][Full Text] [Related]
13. Ferroportin diseases: functional studies, a link between genetic and clinical phenotype.
Détivaud L; Island ML; Jouanolle AM; Ropert M; Bardou-Jacquet E; Le Lan C; Mosser A; Leroyer P; Deugnier Y; David V; Brissot P; Loréal O
Hum Mutat; 2013 Nov; 34(11):1529-36. PubMed ID: 23943237
[TBL] [Abstract][Full Text] [Related]
14. Clinical, pathological, and molecular correlates in ferroportin disease: a study of two novel mutations.
Girelli D; De Domenico I; Bozzini C; Campostrini N; Busti F; Castagna A; Soriani N; Cremonesi L; Ferrari M; Colombari R; McVey Ward D; Kaplan J; Corrocher R
J Hepatol; 2008 Oct; 49(4):664-71. PubMed ID: 18713659
[TBL] [Abstract][Full Text] [Related]
15. Effect of ferroportin polymorphism on iron homeostasis and infection.
Kasvosve I
Clin Chim Acta; 2013 Feb; 416():20-5. PubMed ID: 23178444
[TBL] [Abstract][Full Text] [Related]
16. Structural basis of ferroportin inhibition by minihepcidin PR73.
Wilbon AS; Shen J; Ruchala P; Zhou M; Pan Y
PLoS Biol; 2023 Jan; 21(1):e3001936. PubMed ID: 36649314
[TBL] [Abstract][Full Text] [Related]
17. Hereditary hemochromatosis and transferrin receptor 2.
Chen J; Enns CA
Biochim Biophys Acta; 2012 Mar; 1820(3):256-63. PubMed ID: 21864651
[TBL] [Abstract][Full Text] [Related]
18. Evidence for dimerization of ferroportin in a human hepatic cell line using proximity ligation assays.
Rishi G; Secondes ES; Wallace DF; Subramaniam VN
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32301493
[TBL] [Abstract][Full Text] [Related]
19. Anemic copper-deficient rats, but not mice, display low hepcidin expression and high ferroportin levels.
Jenkitkasemwong S; Broderius M; Nam H; Prohaska JR; Knutson MD
J Nutr; 2010 Apr; 140(4):723-30. PubMed ID: 20164366
[TBL] [Abstract][Full Text] [Related]
20. Disruption of the hepcidin/ferroportin regulatory circuitry causes low axial bone mass in mice.
Ledesma-Colunga MG; Baschant U; Fiedler IAK; Busse B; Hofbauer LC; Muckenthaler MU; Altamura S; Rauner M
Bone; 2020 Aug; 137():115400. PubMed ID: 32380257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
